Tilray Brands, Inc. (NASDAQ:TLRY) Q4 2024 Earnings Conference Call July 29, 2024 4:30 PM ET Company Participants Robert Moskow - TD Cowen Andrew Carter - Stifel Aaron Grey - Alliance Global Partners Owen Bennett - Jefferies Frederico Gomes - ATB Capital Markets Conference Call Participants Berrin Noorata - Chief Corporate Affairs and Communications Officer Irwin Simon - Chairman and CEO Carl Merton - CFO Denise Faltischek - Chief Strategy Officer and Head of International Operator Hello, and thank you for j ...

For the quarter ended May 2024, Tilray Brands, Inc. (TLRY) reported revenue of $229.88 million, up 24.8% over the same period last year. EPS came in at -$0.04, compared to $0.00 in the year-ago quarter. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. Here is how Tilray Brands performed in the just reported quarter in te ...

Tilray Brands, Inc. (TLRY) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to break-even earnings per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -100%. A quarter ago, it was expected that this company would post a loss of $0.04 per share when it actually produced break-even earnings, delivering a surprise of 100%. Over the last four quarters, the company ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38594 TILRAY BRANDS, INC. (Exact name of Registrant as specified in its Charter) Delaware 82-4310622 (State or other jurisdiction of incor ...

Fiscal 2024 Net Revenue Reaches $789 Million, Led by Cannabis Net Revenue of $273 Million and Beverage-Alcohol Net Revenue of $202 Million Tilray Brands, Inc. ("Tilray") (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. Tilray's mis ...

Record Fiscal 2024 Gross Profit Fiscal 2024 Net Revenue Reaches $789 Million, Led by Cannabis Net Revenue of $273 Million and BeverageAlcohol Net Revenue of $202 Million Irwin D. Simon, Chairman and Chief Executive Officer, stated, "Tilray Brands is leading the convergence of cannabis, beverages, and wellness on a global scale. In Fiscal 2024, the Company achieved remarkable growth across its businesses, with a 26% increase in net revenue over the prior year, record-breaking performance in gross profit and ...

Record Fiscal 2024 Gross Profit Fiscal 2024 Net Revenue Reaches $789 Million, Led by Cannabis Net Revenue of $273 Million and BeverageAlcohol Net Revenue of $202 Million NEW YORK and LEAMINGTON, Ontario, and NEÜMUNSTER, Germany, July 29, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray", "our", "we" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a global lifestyle consumer packaged goods company elevating lives through moments of connection, today reported financial results for its fourth quarter and fis ...

TLRY stock also isn't seeing much movement today with a slight gain as of Monday afternoon. Tilray (NASDAQ:TLRY) stock is on the move Monday as investors in the cannabis company react to it securing a trading license in Germany for its Aphria RX subsidiary. Denise Faltischek, Chief Strategy Officer and Head of International at Tilray, said this about the news. Despite the additional license in Germany, TLRY stock isn't seeing much trading today. As of this writing, only about 12 million shares have changed ...

NEUMÜNSTER, Germany, July 29, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray") (NASDAQ:TLRY, TSX:TLRY), a global leader in medical cannabis research, cultivation, production, and distribution, today announced that Aphria RX GmbH ("Aphria RX") has received a trading license, which will allow it to sell and distribute a broad range of medical cannabis products to pharmacies, hospitals, and medical wholesalers throughout Germany. As a leading and trusted medical cannabis company, Tilray strongly believe ...

Tilray Brands Performance and Market Position - Tilray Brands is preparing to announce its Q4 2024 earnings, with investors closely monitoring its performance and strategic direction [1] - The company faces challenges from high excise taxes and price compression in Canada, which have significantly impacted profit margins [2] - Tilray's net revenues are expected to increase by 22.5% year-over-year to $225.7 million in Q4, with a consensus estimate of a loss of 2 cents per share [12] - The company has a trailing four-quarter earnings surprise of 50%, with a 100% margin in the last reported quarter [13] Industry and Regulatory Environment - The cannabis industry is subject to significant regulatory uncertainties and market risks, despite favorable legalization trends [2] - Potential regulatory changes, such as the transition to an Ad Valorem Tax system, could significantly enhance Tilray's profitability [16] - Legislative reforms in Europe, including the removal of medical cannabis from narcotics acts, are expected to boost market penetration [17] Tilray's Strategic Initiatives and Market Reach - Tilray's diversified product innovation, including medical cannabis formats, THC-infused beverages, and pharmaceutical-grade medicines, enhances its ability to capture new market segments globally [14] - The company's focus on organic growth and strategic acquisitions, such as the integration of HEXO and Truss Beverage, underscores its commitment to maximizing revenue opportunities [14] - Tilray has an extensive geographic reach, with 62% of net revenues generated in North America, 36% in EMEA, and 2% from other regions, reducing market risk and leveraging opportunities in different economic environments [15] - In Europe, Tilray maintains a leading position in the medical cannabis market, particularly in Germany, where it holds the highest revenue market share [17] Earnings and Stock Performance Insights - Tilray Brands currently has a Zacks Rank 3 but an Earnings ESP of 0.00%, making an earnings surprise prediction difficult [4] - The Zacks model does not conclusively predict an earnings beat for Tilray this time, despite its Zacks Rank 3 [3] Alternative Investment Opportunities - Chewy, Inc (CHWY) has an Earnings ESP of +1.61% and a Zacks Rank of 1, with expected quarterly revenues of $2.86 billion, a 2.9% year-over-year increase, and earnings per share of 22 cents, up 46.7% from the year-ago quarter [5][6] - Ollie's Bargain (OLLI) has an Earnings ESP of +2.38% and a Zacks Rank of 1, with expected quarterly revenues of $562.4 million, a 9.3% year-over-year increase, and earnings per share of 78 cents, up 16.4% from the year-ago quarter [7][8] - Costco Wholesale Corporation (COST) has an Earnings ESP of +1.23% and a Zacks Rank of 2, with expected quarterly revenues of $80 billion, a 1.3% year-over-year increase, and earnings per share of $5.02, up 3.3% from the year-ago quarter [9][10]